Analysis of major and minor IAS-USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs

Antzeko izenburuak

• Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial
  nork: Clumeck, N, et al.
  Argitaratua: (2010)
• The MONET trial: correlation between Hepatitis C coinfection and HIV RNA responses during darunavir/ritonavir monotherapy, for patients with HIV RNA <50 copies/mL at baseline
  nork: Arribas, Jose R, et al.
  Argitaratua: (2010)
• No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trial.
  nork: Ajantha Solomon, et al.
  Argitaratua: (2014-01-01)
• No Difference in the Rate of Change in Telomere Length or Telomerase Activity in HIV-Infected Patients after Three Years of Darunavir/Ritonavir with and without Nucleoside Analogues in the MONET Trial
  nork: Solomon, Ajantha, et al.
  Argitaratua: (2014)
• Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
  nork: Pasquau, Juan, et al.
  Argitaratua: (2014)